Cumberland Pharmaceuticals CPIX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$7.4M-158% | -$2.86M+14.2% | -$3.34M-14.1% | -$2.93M+11.2% | -$3.29M+48.9% | ||
| $4.39M+5.9% | $4.15M-9.9% | $4.6M-1.7% | $4.68M-2.2% | $4.78M-2.4% | ||
| $440.95K+8.0% | $408.32K+31.3% | $310.97K+1.6% | $306.08K+2.9% | $297.35K-1.5% | ||
| $23K-0.8% | $23.19K-7.3% | $25.02K-17.6% | $30.38K+1.7% | $29.87K+5.5% | ||
| $3.77M-28.0% | $5.24M+696% | -$880.02K— | —— | —— | ||
| -$2.19M+10.8% | -$2.45M+35.3% | -$3.78M-20.0% | -$3.15M+6.6% | -$3.38M-30.9% | ||
| $5.96M-11.1% | $6.71M+504% | -$1.66M— | —— | —— | ||
| -$91.95K-140% | $231.83K— | —— | —— | —— | ||
| -$386.52K+19.1% | -$477.64K— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| $1.14M0.0% | $1.14M0.0% | $1.14M0.0% | $1.14M0.0% | $1.14M0.0% | ||
| -$841.96K-0.7% | -$836.1K-147% | $1.77M-0.3% | $1.77M-0.3% | $1.78M-0.3% | ||
| —— | —— | -$431.5K+53.8% | -$934.91K+21.1% | -$1.19M+18.9% | ||
| $1.42M-71.2% | $4.93M— | —— | —— | —— | ||
| $50.27K-48.6% | $97.9K-2.3% | $100.19K+9.2% | $91.78K+26.6% | $72.47K+9.0% | ||
| $85.36K+1.1% | $84.4K+29.7% | $65.09K-27.0% | $89.17K-22.4% | $114.89K+1.4% | ||
| -$3.83M+23.4% | -$4.99M— | —— | —— | —— | ||
| $78.61K-70.2% | $263.48K-27.2% | $361.86K-19.6% | $450.24K-22.0% | $577.31K-0.3% | ||
| —— | —— | —— | —— | $38.33M+6.5% | ||
| $1.9M+11.2% | $1.71M+14.5% | $1.5M-4.0% | $1.56M-2.5% | $1.6M-7.0% | ||
| -$1.98M+70.6% | -$6.75M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $441.68K-6.7% | $473.57K-6.3% | $505.45K-5.9% | $537.34K-5.6% | ||
| —— | -$3.53K-419% | $1.11K-80.7% | $5.74K-44.7% | $10.37K-30.9% | ||
| $23K-0.8% | $23.19K-7.3% | $25.02K-17.6% | $30.38K+1.7% | $29.87K+5.5% | ||
| —— | —— | -$431.5K+53.8% | -$934.91K+21.1% | -$1.19M+18.9% | ||
| —— | -$13.22K-33.3% | -$9.92K-50.0% | -$6.61K-100% | -$3.31K— | ||
| —— | —— | —— | —— | —— | ||
| -$841.96K-0.7% | -$836.1K-147% | $1.77M-0.3% | $1.77M-0.3% | $1.78M-0.3% | ||
| -$386.52K+19.1% | -$477.64K— | —— | —— | —— | ||
| -$91.95K-140% | $231.83K— | —— | —— | —— | ||
| $1.14M0.0% | $1.14M0.0% | $1.14M0.0% | $1.14M0.0% | $1.14M0.0% | ||
| —— | —— | —— | —— | —— | ||
| $85.36K+1.1% | $84.4K+29.7% | $65.09K-27.0% | $89.17K-22.4% | $114.89K+1.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | $2M+33.3% | $1.5M+50.0% | $1M+100% | $500K— | ||
| —— | —— | —— | —— | -$5.27M— | ||
| —— | —— | —— | —— | $38.33M+6.5% | ||
| —— | $62+100% | -$17.38K+50.1% | -$34.82K+33.4% | -$52.26K+25.0% | ||
| -$841.96K-0.7% | -$836.1K-147% | $1.77M-0.3% | $1.77M-0.3% | $1.78M-0.3% | ||
| —— | $2M+33.3% | $1.5M+50.0% | $1M+100% | $500K— | ||
| $1.9M+11.2% | $1.71M+14.5% | $1.5M-4.0% | $1.56M-2.5% | $1.6M-7.0% | ||
| —— | $4.73K+28.5% | $3.68K+39.9% | $2.63K+66.4% | $1.58K+198% | ||
| —— | —— | —— | —— | —— | ||
| —— | $836.1K-0.8% | $842.91K-0.8% | $849.71K-0.8% | $856.52K-0.8% | ||
| —— | -$3.53K-419% | $1.11K-80.7% | $5.74K-44.7% | $10.37K-30.9% | ||
| $1.37M-71.6% | $4.83M— | —— | —— | —— | ||
| $1.37M-71.6% | $4.83M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cumberland Pharmaceuticals generate?
- Cumberland Pharmaceuticals (CPIX) generated $1.4M in operating cash flow over the trailing twelve months.
- What is Cumberland Pharmaceuticals's free cash flow?
- After $50.3K of capital expenditures, Cumberland Pharmaceuticals's free cash flow was $1.4M over the trailing twelve months, down 23.9% year over year.
- Where does Cumberland Pharmaceuticals's cash flow data come from?
- Every line is extracted from Cumberland Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
